Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
Portfolio Pulse from
Traws Pharma announced positive results for its anti-viral candidate, tivoxavir marboxil, in treating H5N1 bird flu in ferrets, an accepted model for human influenza. This follows similar positive results in a murine model.
March 03, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Traws Pharma's anti-viral candidate, tivoxavir marboxil, showed positive results in treating H5N1 bird flu in ferrets, an accepted model for human influenza. This success follows similar results in a murine model, potentially boosting investor confidence.
The positive results from the ferret model, which is an accepted model for human influenza, suggest potential efficacy in humans. This could lead to increased investor confidence and a positive impact on Traws Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100